Susan Haigney

Elisabeth Gardiner, CSO of Tevard Biosciences, discusses how transfer RNA is impacting the development of gene therapies for diseases with unmet needs.

The company’s new AI agent automates labor-intensive processes involved in trial document management.

The move brings Amgen first-in-class, small molecule-targeted protein degraders for oncology.

Laine Mello, director of marketing at Ecolab Bioprocessing, reflects on how the use of digital technologies expanded in the pharma industry in 2025 and how new complex molecules will continue to drive innovation in 2026.

Chromatin Bioscience, Mediphage Bioceuticals, and Entos Pharmaceuticals will receive advisory services and funding from UKRI Innovate UK and Canada’s NRC IRAP to develop next-generation genetic medicines.

Raj Puri, chief commercial officer at Argonaut Manufacturing, talks about how navigating the pressure to respond to tariffs with investments and keeping a robust and qualified staff are key moves in the new year.

Meri Beckwith, Co-CEO of Lindus Health, provides a look at how trends that developed in 2025 will impact the pharmaceutical industry in 2026.

FUJIFILM Irvine Scientific has changed its name to FUJIFILM Biosciences to better align with the company’s work in cell culture media manufacturing.

ROSS’s DCB-5 Double Cone Tumble Blender can handle high-density materials and provides repeatable homogeneity and powder blending properties, according to the company.

PharmTech spoke with Campbell Bunce, chief scientific officer, Abzena to find out which trends in 2025 impacted the industry the most.

In this overview, PharmTech takes a look back at significant news in the development and approval of cancer treatment in 2025.

David Basile, VP Technical Operations, Americas, Hovione, highlights some common mistakes made by pharmaceutical companies when maintaining manufacturing facilities and equipment.

Pharmaceutical Technology®’s quality experts, Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, a Nelson Labs company, and Siegfried Schmitt, PhD, vice president, Technical at Parexel discuss how pharmaceutical manufacturing training has evolved over the years and how the influx of new facilities is demanding a skilled workforce.

André Cerbe, CEO of Schlafender Hase, spoke with Pharmaceutical Technology® about the disruptions the pharma industry faced in 2025 and how digital workflows will be key for success in 2026.

How will plans to rework medicines legislation in the European Union impact drug development, innovation, and market exclusivity?

Executive Director Emer Cooke presents EMA’s achievements for the year.

In this episode of the Ask the Expert video series, Susan J. Schniepp, Regulatory Compliance Associates (RCA), and Siegfried Schmitt, Parexel, tackle the ever-growing problem of having a properly trained workforce with a variety of needed skill sets.

The agency is approaching the new overhaul as a chance to reshape drug regulations in the European Union.

Co-legislators in Europe have reached a provisional agreement on a new pharmaceutical policy framework to help boost competitiveness, innovation, and supply chain security.

A new facility in Tennessee will boost high-speed pharma packaging capacity and strengthen US supply chain support.

The new Tethered Cap, which will be showcased at 2026 Pharmapack Europe, addresses the demand for sustainability with a TE safety ring that remains attached to the cap.

David Basile, VP Technical Operations, Americas, Hovione, explains what regulators expect for the maintenance of GMP facilities and equipment.

Luca Cavazzini, Sales & Marketing Director at IMA Active, discusses some of the industry’s most common manufacturing challenges, such as sustainability, continuous processes, and technology advancements.

FDA has granted orphan drug designation to FS2 (kynurenic acid) for the investigational treatment of idiopathic pulmonary fibrosis.

Starting with risk mitigation, GMP facility and equipment maintenance is all about anticipating problems before they happen and showing regulators a controlled environment.

The agency is expanding its use of artificial intelligence (AI) with the deployment of agentic AI for staff to create more complex AI workflows and harness AI models.

The first patient visit has taken place for the SURMOUNT-REAL UK clinical trial of Eli Lilly and Company’s weight-loss drug, tirzepatide.

In this episode of the Ask the Expert video series, Susan J. Schniepp, Regulatory Compliance Associates (RCA), Siegfried Schmitt, Parexel, and Anita Michaels, RCA, explain how CDMOs can best handle regulatory inspections and client expectations.

In a poster presentation at AAPS PharmSci 360, Eda Fenercioglu, a scientist at Pfizer, outlines a streamline workflow for identifying and mitigating visible particles in biologic drugs.

Pharmaceutical Technology® spoke with Steve Lowes, senior director of Scientific Affairs at IQVIA Laboratories, ahead of AAPS PharmSci 360 to discuss some of the unique instruments used to conduct bioanalysis.